



Biostatistics Collaboration Unit (BCU)

Prof Andy Vail



Role of Statistics in Translational research

Basic Science: "In the basic biological sciences, statistical considerations are secondary or nonexistent, results entirely unpredicted by hypotheses are celebrated, and there are few formal rules for reproducibility"

Translation usually involves: Collection/collation of quantitative data for analysis and interpretation.

ICH Good Clinical Practice: "it is assumed that the actual responsibility for all statistical work associated with clinical trials will lie with an appropriately qualified and experienced statistician"



Typical funding model

Senior Statistical co-applicant

Expertise in design, analysis and interpretation

Co-applicant or Named Collaborator as appropriate

Small percentage supervision time

RA/RF (Grade 5 to 7) Biostatistician to

Agree data collection & management mechanisms

Pre-specify statistical analysis plan

Undertake data validation and check assumptions

Code analyses, graphs, tables

Co-author results and discussion sections

Time consuming: typically ≥ 30% FTE



Advantages

Full recovery of costs: pleases Faculty

Statistical work by professional statisticians: pleases funders

Higher quality publications: pleases research team

Possible to appoint to part-time, short-term posts

Cover for prolonged absences

Contact

https://sites.manchester.ac.uk/biostatistics/

Email: biostatsenquiries@manchester.ac.uk



Diagnostics and Technology Accelerator

Annie Yarwood

DITA



Diagnostics and Technology Accelerator

DiTA works <u>collaboratively</u> with innovators to <u>catalyse</u> high quality <u>evidence</u> generation for new IVDs and MedTech which can be commercialised, facilitating rapid translation and adoption into the health and care system.

Co-development

 Working with industry, academics, clinicians, patients and the public to co-develop devices to improve patient care and efficiency within the NHS

Partnership

• Establishing partnerships between industry, academics, patients, NHS, clinicians, and wider infrastructure, to progress innovations

Collaboration

Collaborative grant applications

Director: Dr Tim Felton




Operations manager: Annie Yarwood

DiTAs focus is Evidence Generation



Our activity is Based around 3 pillars:





VALIDATE platform

InnoVative ObservAtionaL In-vitro DiAgnosTic pErformance study

Platform project with master protocol and over-arching ethics where projects can be added as amendments as and when they arise

Allow us to be responsive – rapid costings, approval, set up and delivery

The study is **disease and infection agnostic** – study a wide range of diagnostics targeting different conditions

VALIDATE will cover **observational studies**, samples will be collected prospectively

Transform the speed at which new diagnostics can progress through the innovation pipeline towards patient benefit.

TranslationManchester Research Network

Research Design Service North West

Sarah Rhodes

The Research Design Service



Sarah Rhodes

RDS frontline advisor/Statistician





Research Design Service North West

Provides advice on research design to researchers to develop high quality research proposals for national, peer-reviewed funding competitions for applied health or social care research.



Our expertise

- Methodology including but not limited to:
 - quantitative, including statistical
 - qualitative
 - mixed methods
 - health economics
 - health psychology and behaviour change
 - specialist methodologies.
- Specific funding programme application advice.



See www.rds-nw.nihr.ac.uk/about-us/expertise-a-z for more examples



We can also help with

- Identifying appropriate funding.
- Finding collaborators and building an appropriate team.
- Involving the public.
- Formulating the research question.
- "Grantsmanship."
- Signposting to specialised support.
- Ethical and governance issues.
- Getting the narrative right.
- A critical read of your proposal.
- And much more.









Bionow

David Holmes

bionow.

What is Bionow?



A Resource to Expand your network
100s of Life Science & Biomedical Companies
To Connect you to the sector
& Save money – lots of it!

Why?

Meet other Academics
Meet Industry
Connect with Collaboration Partners
Connect with Professionals and Expertise
Funding Opportunities
Save Money – lots of it!























bionow.




















News/Newsletter



Biotech & Beers, Business Pitching, Coffee Mornings and more....



Life Scientist Come over for a chat...

(Stand 28 - Pioneer Suite)





















Commercial Partnerships, CRUK

Martyn Bottomley



Martyn Bottomley, Commercial Partnerships Team

SUPPORT AVAILABLE TO RESEARCHERS



COMMERCIALISATION AND INDUSTRY ENGAGEMENT



A department dedicated to helping you accelerate your discoveries to patients



A regional team to support you through the research translation process

ENTREPRENEURIAL PROGRAMMES



Educational, training and financial support programmes to equip you with the knowledge and skills to commercialise your research

DEDICATED TRANSLATION FUNDING, INFRASTRUCTURE & PLATFORMS



Access to therapeutic discovery and development capabilities



Translational grant funding to progress drugs, devices, diagnostics, data and software



Seed and venture capital funds

COMMERCIAL GAP FUNDING

Funding to bridge the gap to commercialisation



PROJECT DEVELOPMENT FUND (typically 'Fast50' £50k awards)

PATENT COSTS* (as required)

SEED FUND (£15-30m Fund – equity investments or convertible loans from £50k pre-seed to £1m seed/series A)

SV7 IMPACT MEDICINE FUND (£275m)

*where patent protection is appropriate

TranslationManchester Research Network

University of Manchester Innovation Factory

Duncan Henderson

The University of Manchester Innovation Factory

'Commercialising
The University of Manchester's
innovations and IP to create
positive economic & social impact'

Dr Duncan Henderson – Director of Projects Life Sciences

Duncan.Henderson@uominnovationfactory.com

+44 (0) 7917 422297 (work mobile)

Translational Research @ Manchester 2022



Why?











Worldwide Industrial Investment






The University of Manchester



Revenue Share



What?



We protect and commercialise University IP



Commercialisation in a university setting involves capturing innovations through the identification of Intellectual Property (IP)

The University needs to own the IP – it may not, it may be shared...

Various forms of IP can be protected and can be of value

patents copyright materials Knowhow Data code assays

| Innovation Factory output: last 3 years | 2019/20 | 2020/21 | 2021/22 |
|---|---------|---------|---------|
| New Invention disclosures | 90 | 80 | 120 |
| Spinout companies | 9 | 13 | 10 |
| Licencing income | £1.5m | £7.4m | £4.9m |
| First investment in sninguts | | f3./m | f6.3m |



Funding



n

On the road to

commercialisation how can we

help?.....



Market research



Grant application support





Consultants





Project planning



Training/mentoring

Who?



Duncan Henderson Director of Life Sciences



The Life Sciences Team



Joannah Denbigh



Yousef Taktak



Sam Rhoden



Sonia Nikolovski



Ewalina Rozyka



Tansi Khodai



Ida Jackson



Nathalie Dhomen

Cancer







Elliot Jennings

BUSINESS DEVELOPMENT

OPERATIONS

Lifescience Spinouts Launched in last 3 years

- Complement Therapeutics Ltd Complement therapeutic for age related macular degeneration. Simon Clarke SBS
- **VREvo Ltd** Virtual reality medical teaching tool. Anthony Payton. SHS
- InPepCide Anti-Fungal. Mike Bromley SBS
- Gene Gini Transcriptomic frequency analysis software. Philip Day SBS
- Careloop Mental Health platform & app. Lewis Schon SHS
- Link Biologics Osteoarthritis Therapeutics. Tony MiTrial clinical trial organisation software. Day. SBS
- Ravan Anti Viral Therapeutics and Senesce. Ian Imperagen Enzyme engineering. Andrew Hampson SMS
- **Barran** MIB Chemistry

- Mantra Hypoxic Tumour Biomarkers. Catherine West SMS
- **Spotlight** AI for pathology analysis in Blood Cancer Martin Fergie SHS
- Tabrix Tuberculosis Therapeutics. Lydia Tabernero, SBS
- Retendon Synthetic Tendon Repair device. Sarah Cartmell. SNS Materials
- **PolyNerve** Synthetic Nerve Repair **Sandra Downes** SNS materials
- Alexander Horsley SBS
- Almond et al. MIB Chemistry
- Sebomix Early Diagnostics for Parkinson's. Perdi Apini eNAMPT small molecule. Sam Butterworth

Fin

